{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:55:17Z","timestamp":1788609317958,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"am","delay-in-days":197,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5UG3DA048775-02"],"award-info":[{"award-number":["5UG3DA048775-02"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.biomaterials.2025.123776","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:36:11Z","timestamp":1760196971000},"page":"123776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["IFN-\u03b3 and TLR agonist co-adjuvants enhance the efficacy of a lipid-PLGA hybrid nanoparticle-based oxycodone vaccine"],"prefix":"10.1016","volume":"327","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0585-3251","authenticated-orcid":false,"given":"Yuanzhi","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiao","family":"Ci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobra","family":"Rostamizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Marecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"DeHority","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6770-5334","authenticated-orcid":false,"given":"Chenming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biomaterials.2025.123776_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.biomaterials.2025.123776_bib2","series-title":"Prescription Opioids Drugfacts","year":"2021"},{"key":"10.1016\/j.biomaterials.2025.123776_bib3","series-title":"Prescription Opioid Use is a Risk Factor for Heroin Use","year":"2018"},{"key":"10.1016\/j.biomaterials.2025.123776_bib4","series-title":"Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration","article-title":"2023 Companion infographic report: Results from the 2021, 2022, and 2023 National Surveys on Drug Use and Health (SAMHSA Publication No. PEP24-07-020)","year":"2024"},{"key":"10.1016\/j.biomaterials.2025.123776_bib5","series-title":"Medications for Opioid Use Disorder","year":"2025"},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14737167.2024.2350561","article-title":"Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies","volume":"24","author":"Jalali","year":"2024","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"6","key":"10.1016\/j.biomaterials.2025.123776_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.biomaterials.2025.123776_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"issue":"8","key":"10.1016\/j.biomaterials.2025.123776_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biomaterials.2025.123776_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1141093","article-title":"Barriers to opioid use disorder treatment: a comparison of self-reported information from social media with barriers found in literature","volume":"11","author":"Bremer","year":"2023","journal-title":"Front. Public Health"},{"key":"10.1016\/j.biomaterials.2025.123776_bib11","first-page":"2020","article-title":"Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system","author":"Madras","year":"2020","journal-title":"NAM Perspect."},{"key":"10.1016\/j.biomaterials.2025.123776_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2024.116660","article-title":"Barriers to opioid use disorder treatment among people who use drugs in the rural United States: a qualitative, multi-site study","volume":"346","author":"Stopka","year":"2024","journal-title":"Soc. Sci. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123776_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/1073110518782951","article-title":"Improving rural access to opioid treatment programs","volume":"46","author":"Johnson","year":"2018","journal-title":"J. Law Med. Ethics"},{"key":"10.1016\/j.biomaterials.2025.123776_bib14","series-title":"Naloxone, in StatPearls","author":"Jordan","year":"2025"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12954-022-00682-w","article-title":"Naloxone administration by law enforcement officers in New York state (2015-2020)","volume":"19","author":"Pourtaher","year":"2022","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.biomaterials.2025.123776_bib16","series-title":"Naloxone Drugfacts","year":"2022"},{"key":"10.1016\/j.biomaterials.2025.123776_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drugpo.2019.09.008","article-title":"Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA","volume":"74","author":"Bessen","year":"2019","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.biomaterials.2025.123776_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1346109","article-title":"Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids","volume":"12","author":"Dahan","year":"2024","journal-title":"Front. Public Health"},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123776_bib19","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3390\/vaccines10111778","article-title":"Immunotherapies for the treatment of drug addiction","volume":"10","author":"Hossain","year":"2022","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123776_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13543784.2023.2187286","article-title":"The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis","volume":"32","author":"Martinez","year":"2023","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update","volume":"6","author":"Pathan","year":"2012","journal-title":"Br. J. Pain"},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123776_bib22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.tips.2018.08.001","article-title":"Immunopharmacotherapies for treating opioid use disorder","volume":"39","author":"Banks","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123776_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyaf005","article-title":"The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention","volume":"28","author":"Tuncturk","year":"2025","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123776_bib24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.vaccine.2023.12.077","article-title":"A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood","volume":"42","author":"Romano","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.biomaterials.2025.123776_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108348","article-title":"A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys","volume":"218","author":"Townsend","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.biomaterials.2025.123776_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat opioid use disorders and reduce incidence of overdose","volume":"158","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41541-025-01083-3","article-title":"Product and trial design considerations on the path towards a vaccine to combat opioid overdose","volume":"10","author":"Angelidou","year":"2025","journal-title":"npj Vaccines"},{"issue":"Suppl 1","key":"10.1016\/j.biomaterials.2025.123776_bib28","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1093\/cid\/ciac344","article-title":"Acceptability of a fentanyl vaccine to prevent opioid overdose and need for personalized decision-making","volume":"75","author":"Weitzman","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"25","key":"10.1016\/j.biomaterials.2025.123776_bib29","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1021\/jacs.7b03334","article-title":"Development of a clinically viable heroin vaccine","volume":"139","author":"Bremer","year":"2017","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123776_bib30","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1021\/acs.bioconjchem.1c00179","article-title":"Bivalent conjugate vaccine induces dual immunogenic response that attenuates heroin and fentanyl effects in mice","volume":"32","author":"Barrientos","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biomaterials.2025.123776_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107730","article-title":"Vaccine blunts fentanyl potency in male rhesus monkeys","volume":"158","author":"Tenney","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.biomaterials.2025.123776_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122758","article-title":"The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines","volume":"313","author":"Walter","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2025.123776_bib112","doi-asserted-by":"crossref","first-page":"114294","DOI":"10.1016\/j.jconrel.2025.114294","article-title":"Innate immune mechanisms underlying the efficacy of a next-generation nanoparticle-based vaccine against opioid use disorders","author":"Hamid","year":"2025","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/10915818251355948","article-title":"Safety and toxicological evaluation of subunit Keyhole limpet hemocyanin-loaded Lipid\u2013PLGA hybrid nanoparticles (sKLH-hNPs) as a nanocarrier for an opioid use disorder vaccine","volume":"44","author":"Walter","year":"2025","journal-title":"Int. J. Toxicol."},{"issue":"Pt 7","key":"10.1016\/j.biomaterials.2025.123776_bib35","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1099\/jmm.0.038943-0","article-title":"Alum adjuvant: some of the tricks of the oldest adjuvant","volume":"61","author":"Kool","year":"2012","journal-title":"J. Med. Microbiol."},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123776_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071884","article-title":"Aluminum Adjuvants-'Back to the future'","volume":"15","author":"Laera","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.biomaterials.2025.123776_bib37","article-title":"Basic properties and development status of aluminum adjuvants used for vaccines","volume":"12","author":"Lan","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123776_bib38","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative safety of vaccine adjuvants: A summary of current evidence and future needs","volume":"38","author":"Petrovsky","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.biomaterials.2025.123776_bib39","article-title":"Toll-Like receptor 4 (TLR4)\/Opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2025.123776_bib40","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/bph.12028","article-title":"Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4","volume":"168","author":"Stevens","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.biomaterials.2025.123776_bib41","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.1202658","article-title":"Morphine prevents lipopolysaccharide-induced TNF secretion in mast cells blocking I\u03baB kinase activation and SNAP-23 phosphorylation: correlation with the formation of a \u03b2-Arrestin\/TRAF6 complex","volume":"191","author":"Madera-Salcedo","year":"2013","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123776_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.biomaterials.2025.123776_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05069.x","article-title":"Clinical use of interferon-Gamma","volume":"1182","author":"Miller","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123776_bib44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.antiviral.2011.04.001","article-title":"Interferon-\u03b3 influences immunity elicited by vaccines against very virulent Marek's disease virus","volume":"90","author":"Haq","year":"2011","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41434-021-00270-w","article-title":"Adjuvant properties of IFN-\u03b3 and GM-CSF in the scFv6.C4 DNA vaccine against CEA-expressing tumors","volume":"30","author":"Zanetti","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.biomaterials.2025.123776_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.dci.2021.104159","article-title":"Immune adjuvant effects of interferon-gamma (IFN-\u03b3) of flounder (Paralichthys olivaceus) against Edwardsiella tarda","volume":"123","author":"Wang","year":"2021","journal-title":"Dev. Comp. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib47","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3390\/v15051198","article-title":"Efficiency of Interferon-\u03b3 in activating dendritic cells and its potential synergy with toll-like receptor agonists","volume":"15","author":"Bian","year":"2023","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.biomaterials.2025.123776_bib48","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/pharmaceutics17091223","article-title":"Precision adjuvant strategies in vaccine development for substance use disorders: variability and mechanistic insights","volume":"17","author":"Bian","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123776_bib49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nano.2016.07.015","article-title":"A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy","volume":"13","author":"Zhao","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biomaterials.2025.123776_bib50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.biomaterials.2017.11.021","article-title":"Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction","volume":"155","author":"Zhao","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2025.123776_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.biomaterials.2017.01.038","article-title":"Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: a focus on hapten density","volume":"123","author":"Zhao","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2025.123776_bib52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biomaterials.2017.05.031","article-title":"Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: a focus on hapten localization","volume":"138","author":"Zhao","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2025.123776_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2019.102023","article-title":"Alum as an adjuvant for nanoparticle based vaccines: a case study with a hybrid nanoparticle-based nicotine vaccine","volume":"20","author":"Hu","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4161\/hv.26635","article-title":"A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle","volume":"10","author":"Hu","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123776_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse","volume":"12","author":"Raleigh","year":"2017","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.biomaterials.2025.123776_bib56","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1016\/j.vaccine.2022.03.053","article-title":"Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder","volume":"40","author":"Hamid","year":"2022","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib57","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.nano.2018.04.016","article-title":"Hybrid nanoparticle-based nicotine nanovaccines: boosting the immunological efficacy by conjugation of potent carrier proteins","volume":"14","author":"Zhao","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"23","key":"10.1016\/j.biomaterials.2025.123776_bib58","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.1021\/acs.jmedchem.0c01042","article-title":"Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity","volume":"63","author":"Robinson","year":"2020","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib59","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bja\/aeq212","article-title":"Effects of capsazepine, a transient receptor potential vanilloid type 1 antagonist, on morphine-induced antinociception, tolerance, and dependence in mice","volume":"105","author":"Nguyen","year":"2010","journal-title":"Br. J. Anaesth."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib60","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1734-1140(12)70912-X","article-title":"Anti-inflammatory and antinociceptive effects of 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine in mice","volume":"64","author":"Yu","year":"2012","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43689-4","article-title":"Application of ensemble machine learning approach to assess the factors affecting size and polydispersity index of liposomal nanoparticles","volume":"13","author":"Hoseini","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biomaterials.2025.123776_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.867119","article-title":"Biological nanoparticles in vaccine development","volume":"10","author":"Curley","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.biomaterials.2025.123776_bib63","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.2147\/IJN.S215415","article-title":"Co-delivery of allergen epitope fragments and R848 inhibits food allergy by inducing tolerogenic dendritic cells and regulatory T cells","volume":"14","author":"Hong","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2025.123776_bib64","article-title":"Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biomaterials.2025.123776_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.966113","article-title":"OVA-PEG-R848 nanocapsules stimulate neonatal conventional and plasmacytoid dendritic cells","volume":"10","author":"Wirsching","year":"2022","journal-title":"Front Pediatr"},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.549","article-title":"Toll-like receptors in health and disease","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123776_bib67","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12026-021-09203-6","article-title":"TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review","volume":"69","author":"Komal","year":"2021","journal-title":"Immunol. Res."},{"issue":"9","key":"10.1016\/j.biomaterials.2025.123776_bib68","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.imbio.2010.05.008","article-title":"Dissecting TLR3 signalling in dendritic cells","volume":"215","author":"Gauzzi","year":"2010","journal-title":"Immunobiology"},{"issue":"23","key":"10.1016\/j.biomaterials.2025.123776_bib69","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1158\/1078-0432.CCR-12-2189","article-title":"Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients","volume":"18","author":"Sabbatini","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123776_bib70","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4049\/jimmunol.1402033","article-title":"TLR3-Mediated CD8+ dendritic cell activation is coupled with establishment of a cell-intrinsic antiviral state","volume":"195","author":"Sz\u00e9les","year":"2015","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib71","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40364-022-00436-7","article-title":"Targeting toll-like receptor 7\/8 for immunotherapy: recent advances and prospectives","volume":"10","author":"Sun","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biomaterials.2025.123776_bib72","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fimmu.2020.617522","article-title":"R848 is involved in the antibacterial immune response of golden Pompano (Trachinotus ovatus) through TLR7\/8-MyD88-NF-\u03baB-Signaling pathway","volume":"11","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2025.123776_bib73","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/pharmaceutics14061228","article-title":"The role of toll-like receptor agonists and their nanomedicines for tumor immunotherapy","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"14","key":"10.1016\/j.biomaterials.2025.123776_bib74","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/1078-0432.CCR-06-2949","article-title":"Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"13","author":"Sabbatini","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biomaterials.2025.123776_bib75","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2010-0307","article-title":"Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer","volume":"16","author":"Miles","year":"2011","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13046-021-02017-2","article-title":"A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy","volume":"40","author":"De Waele","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib77","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1371\/journal.pmed.0030006","article-title":"EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice","volume":"3","author":"Shir","year":"2006","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123776_bib78","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3390\/ph3041162","article-title":"Safety, tolerability, and immunogenicity of interferons","volume":"3","author":"Tovey","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"10.1016\/j.biomaterials.2025.123776_bib79","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1021\/acs.biomac.0c00812","article-title":"Nanoparticles presenting potent TLR7\/8 agonists enhance Anti-PD-L1 immunotherapy in cancer treatment","volume":"21","author":"Smith","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biomaterials.2025.123776_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123032","article-title":"PPS-TLR7\/8 agonist nanoparticles equip robust anticancer immunity by selectively prolonged activation of dendritic cells","volume":"316","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2025.123776_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102402","article-title":"ROS-responsive TLR7\/8 nanoagonist and ultrasound modulate dendritic cells antigen presentation","volume":"57","author":"Ren","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.biomaterials.2025.123776_bib82","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fimmu.2023.1334800","article-title":"Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors","volume":"14","author":"Anfray","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2025.123776_bib83","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/925135","article-title":"CD4+T cells: differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib84","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41541-021-00330-7","article-title":"Protein-based antigen presentation platforms for nanoparticle vaccines","volume":"6","author":"Nguyen","year":"2021","journal-title":"npj Vaccines"},{"issue":"23","key":"10.1016\/j.biomaterials.2025.123776_bib85","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.2217\/nnm-2017-0254","article-title":"Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer","volume":"12","author":"Chesson","year":"2017","journal-title":"Nanomedicine (Lond)"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib86","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12951-023-02022-x","article-title":"Advances in nanomedicines for lymphatic imaging and therapy","volume":"21","author":"He","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123776_bib87","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.4049\/jimmunol.1101044","article-title":"Dendritic cells activated by IFN-\u03b3\/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment","volume":"188","author":"Horejs-Hoeck","year":"2012","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib88","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1189\/jlb.0107040","article-title":"Regulation of STAT pathways and IRF1 during human dendritic cell maturation by TNF-alpha and PGE2","volume":"84","author":"Hu","year":"2008","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib89","article-title":"Mechanisms of mixed Th1\/Th2 responses in mice induced by Albizia julibrissin Saponin active fraction by in silico analysis","volume":"8","author":"Du","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123776_bib90","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/vaccines1030328","article-title":"Isotype diversification of IgG antibodies to HIV gag proteins as a therapeutic vaccination strategy for HIV infection","volume":"1","author":"French","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biomaterials.2025.123776_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib92","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"24","key":"10.1016\/j.biomaterials.2025.123776_bib93","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib94","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2011.281","article-title":"Vaccines against drug abuse","volume":"91","author":"Shen","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123776_bib95","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pbb.2009.01.015","article-title":"Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence","volume":"92","author":"Moreno","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"9","key":"10.1016\/j.biomaterials.2025.123776_bib96","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.biomaterials.2025.123776_bib97","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123776_bib113","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4049\/jimmunol.2100204","article-title":"Contribution of antibody-mediated effector functions to the mechanism of efficacy of vaccines for opioid use disorders","volume":"207","author":"Huseby Kelcher","year":"2021","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib114","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4049\/jimmunol.2400170","article-title":"Monoclonal antibodies engineered with Fc region mutations to extend protection against fentanyl toxicity","volume":"213","author":"Khaimraj","year":"2024","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123776_bib98","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/jm3013745","article-title":"Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens","volume":"56","author":"Pravetoni","year":"2013","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123776_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101807","article-title":"Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.biomaterials.2025.123776_bib100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123776_bib101","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2003","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.biomaterials.2025.123776_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2025.123776_bib103","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib104","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","article-title":"TLR signaling","volume":"13","author":"Kawai","year":"2006","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.biomaterials.2025.123776_bib105","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nri1900","article-title":"IRFs: master regulators of signalling by toll-like receptors and cytosolic pattern-recognition receptors","volume":"6","author":"Honda","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.biomaterials.2025.123776_bib106","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biomaterials.2025.123776_bib107","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-065X.2008.00707.x","article-title":"Regulation of interferon and toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms","volume":"226","author":"Hu","year":"2008","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123776_bib108","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1084\/jem.20151722","article-title":"IFN-\u03b3 receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity","volume":"213","author":"Domeier","year":"2016","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123776_bib109","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/pharmaceutics16010084","article-title":"Vaccines to treat substance use disorders: current status and future directions","volume":"16","author":"Lu","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biomaterials.2025.123776_bib110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biochi.2020.08.019","article-title":"Antibody stability: a key to performance - analysis, influences and improvement","volume":"177","author":"Ma","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.biomaterials.2025.123776_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.856961","article-title":"Physiological considerations for modeling in vivo antibody-target interactions","volume":"13","author":"Dunlap","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225006957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225006957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:51:04Z","timestamp":1780476664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961225006957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":114,"alternative-id":["S0142961225006957"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123776","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFN-\u03b3 and TLR agonist co-adjuvants enhance the efficacy of a lipid-PLGA hybrid nanoparticle-based oxycodone vaccine","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123776"}}